Name: Pediatric Formulations: A Roadmap (en Inglés)
Price: 208.95 USD
Availability: InStock
Author: Bar-Shalom, Daniel ; Rose, Klaus
ISBN: 9781493945214

portada Pediatric Formulations: A Roadmap (en Inglés)

Pediatric Formulations: A Roadmap (en Inglés)

Formato

Libro Físico

Editorial

Springer

Autor

Bar-Shalom, Daniel ; Rose, Klaus

Idioma

Inglés

N° páginas

439

Encuadernación

Tapa Blanda

Dimensiones

23.4 x 15.6 x 2.3 cm

Peso

0.64 kg.

ISBN13

9781493945214

Categorías

Pediatría
Farmacia/prescripción/dispensación
Química orgánica

Pediatric Formulations: A Roadmap (en Inglés)

Bar-Shalom, Daniel ; Rose, Klaus (Autor) · Springer · Tapa Blanda

Libro Nuevo Importado

Envío: 16 a 23 días háb.

$ 379.91$ 208.95

-45%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

$ 208.95

Llega entre el 03 Sep y el 16 Sep a Quito, Pichincha. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Pediatric Formulations: A Roadmap (en Inglés)"

Until the 1990s, it was generally accepted that medicines were first developed for adults and their use in children was investigated later, if at all. One of the main tasks of hospital pharmacies was the manufacturing of child-appropriate formulations in a more or less makeshift way. The first change came in 1997 with U.S. legislation that rewarded manufacturers to do voluntary pediatric research. Ten years later, the European Union passed legislation that required manufacturers to discuss all pediatric aspects, including formulations, with the regulatory authorities as a condition of starting the registration procedure. In consequence, manufacturers must now cover all age groups, including the youngest ones. So far, pediatric formulations were more a focus for academic researchers. Through the changed regulatory environment, there is now a sudden high commercial demand for age-appropriate formulations. This book begins by highlighting the anatomical, physiological and developmental differences between adults and children of different ages. It goes on to review the existing technologies and attempts to draw a roadmap to better, innovative formulations, in particular for oral administration. The regulatory, clinical, ethical and pharmaceutical framework is also addressed.